Search results
Results from the WOW.Com Content Network
Glimepiride is an antidiabetic medication within the sulfonylurea class, primarily prescribed for the management of type 2 diabetes. [ 1 ] [ 2 ] It is regarded as a second-line option compared to metformin , due to metformin's well-established safety and efficacy. [ 1 ]
Take liquid metformin at the same time each day and with food. Just like with the tablet version, make it a habit to take liquid metformin at the same time to avoid missing doses and with food.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood.With the exception of insulin, most GLP-1 receptor agonists (liraglutide, exenatide, and others), and pramlintide, all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.
[1] [2] It is not indicated for use by itself in type 1 diabetes. [1] [2] It is taken by mouth. [1] [2] Effects generally begin within half an hour and can last for up to a day. [1] Common side effects include nausea, diarrhea, low blood sugar, and headache. [1] Other side effects include sleepiness, skin rash, and shakiness. [3]
If a patient using an alpha-glucosidase inhibitor suffers from an episode of hypoglycemia, the patient should eat something containing monosaccharides, such as glucose tablets. Since the drug will prevent the digestion of polysaccharides (or non-monosaccharides), non-monosaccharide foods may not effectively reverse a hypoglycemic episode in a ...
Common adverse effects over 10%: [13] Hypoglycemia (11 - 12%) - while it was shown to have the same efficacy as glimepiride, one of the newer sulfonylureas, the European GUIDE study has shown that it has approximately 50% less hypoglycemic confirmed episodes in comparison with glimepiride. [14] Uncommon adverse effect between 1 - 10%: [13]
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.